In 2019, iRhythm launched the Zio AT, which added a wearable cellular gateway to transmit patient data back to the Company. Marketed by iRhythm as a mobile cardiac telemetry (MCT) device, this transmission capability is meant to enable real-time surveillance and notification to doctors of cardiac events for more acute patients. Heralded by the Company as a disruptive product that would incrementally increase its addressable market, the Zio AT has been the subject of intense regulatory scrutiny for potentially fatal product flaws. As a company that has long been focused on a single product, single market, and single application, iRhythm has increasingly pitched investors on a breadth of emerging growth opportunities, including the targeting of asymptomatic patients, a new MCT product, and international expansion, to name a few.